KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $11.4 million.

  • Vir Biotechnology's Share-based Compensation fell 3198.78% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.7 million, marking a year-over-year decrease of 4090.86%. This contributed to the annual value of $78.5 million for FY2024, which is 2951.87% down from last year.
  • According to the latest figures from Q3 2025, Vir Biotechnology's Share-based Compensation is $11.4 million, which was down 3198.78% from $12.5 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Share-based Compensation high stood at $30.6 million for Q2 2023, and its period low was $11.4 million during Q3 2025.
  • Over the past 5 years, Vir Biotechnology's median Share-based Compensation value was $23.8 million (recorded in 2024), while the average stood at $21.8 million.
  • In the last 5 years, Vir Biotechnology's Share-based Compensation soared by 42143.58% in 2021 and then plummeted by 4396.93% in 2024.
  • Vir Biotechnology's Share-based Compensation (Quarter) stood at $24.4 million in 2021, then increased by 2.03% to $24.9 million in 2022, then increased by 13.7% to $28.3 million in 2023, then tumbled by 43.97% to $15.8 million in 2024, then dropped by 28.31% to $11.4 million in 2025.
  • Its Share-based Compensation stands at $11.4 million for Q3 2025, versus $12.5 million for Q2 2025 and $14.1 million for Q1 2025.